BAVA Stock Overview
Develops, manufactures, and commercializes life-saving vaccines.
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 1/6 |
Past Performance | 4/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
Bavarian Nordic A/S Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | DKK 181.00 |
52 Week High | DKK 191.40 |
52 Week Low | DKK 125.55 |
Beta | 1.47 |
11 Month Change | -0.98% |
3 Month Change | 21.60% |
1 Year Change | 25.87% |
33 Year Change | -28.88% |
5 Year Change | -0.22% |
Change since IPO | -29.02% |
Recent News & Updates
Recent updates
Bavarian Nordic A/S' (CPH:BAVA) Shareholders Might Be Looking For Exit
Jul 11Results: Bavarian Nordic A/S Delivered A Surprise Loss And Now Analysts Have New Forecasts
May 12Improved Revenues Required Before Bavarian Nordic A/S (CPH:BAVA) Shares Find Their Feet
Apr 09Does Bavarian Nordic (CPH:BAVA) Have A Healthy Balance Sheet?
Feb 26Bavarian Nordic A/S' (CPH:BAVA) Business And Shares Still Trailing The Industry
Jan 03Bavarian Nordic A/S (CPH:BAVA) Shares Could Be 45% Below Their Intrinsic Value Estimate
Dec 10Here's Why Bavarian Nordic (CPH:BAVA) Can Manage Its Debt Responsibly
Nov 15Does Bavarian Nordic (CPH:BAVA) Have A Healthy Balance Sheet?
Aug 17Improved Revenues Required Before Bavarian Nordic A/S (CPH:BAVA) Shares Find Their Feet
Apr 19Is Bavarian Nordic (CPH:BAVA) Weighed On By Its Debt Load?
Jan 03Bavarian Nordic (CPH:BAVA) Has Debt But No Earnings; Should You Worry?
Sep 15Rainbows and Unicorns: Bavarian Nordic A/S (CPH:BAVA) Analysts Just Became A Lot More Optimistic
Jul 24Industry Analysts Just Made A Notable Upgrade To Their Bavarian Nordic A/S (CPH:BAVA) Revenue Forecasts
Jun 14Analyst Forecasts Just Became More Bearish On Bavarian Nordic A/S (CPH:BAVA)
May 31Is Bavarian Nordic (CPH:BAVA) Using Debt In A Risky Way?
May 06Bavarian Nordic A/S (CPH:BAVA) Analysts Just Cut Their EPS Forecasts Substantially
Mar 13Shareholder Returns
BAVA | DK Biotechs | DK Market | |
---|---|---|---|
7D | -2.2% | 3.2% | -1.5% |
1Y | 25.9% | 0.8% | 31.9% |
Return vs Industry: BAVA exceeded the Danish Biotechs industry which returned 2.5% over the past year.
Return vs Market: BAVA underperformed the Danish Market which returned 31% over the past year.
Price Volatility
BAVA volatility | |
---|---|
BAVA Average Weekly Movement | 6.9% |
Biotechs Industry Average Movement | 7.4% |
Market Average Movement | 4.3% |
10% most volatile stocks in DK Market | 9.0% |
10% least volatile stocks in DK Market | 2.6% |
Stable Share Price: BAVA has not had significant price volatility in the past 3 months.
Volatility Over Time: BAVA's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of Danish stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1992 | 1,381 | Paul Chaplin | www.bavarian-nordic.com |
Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase III clinical trial for the treatment of SARS-CoV-2.
Bavarian Nordic A/S Fundamentals Summary
BAVA fundamental statistics | |
---|---|
Market cap | DKK 14.09b |
Earnings (TTM) | DKK 984.37m |
Revenue (TTM) | DKK 6.64b |
14.3x
P/E Ratio2.1x
P/S RatioIs BAVA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
BAVA income statement (TTM) | |
---|---|
Revenue | DKK 6.64b |
Cost of Revenue | DKK 2.04b |
Gross Profit | DKK 4.60b |
Other Expenses | DKK 3.62b |
Earnings | DKK 984.37m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 22, 2024
Earnings per share (EPS) | 12.65 |
Gross Margin | 69.29% |
Net Profit Margin | 14.82% |
Debt/Equity Ratio | 0.2% |
How did BAVA perform over the long term?
See historical performance and comparison